[
  {
    "question": "Patient came after hysterectomy, there is hip flexion, knee extension weakness.",
    "option_a": "Femoral",
    "option_b": "obturator",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "The femoral nerve supplies the anterior thigh muscles, including the iliopsoas (hip flexors) and the quadriceps (knee extensors). Injury to this nerve results in weakness in hip flexion and knee extension \u2013 the very deficits seen in this patient post\u2010hysterectomy. During pelvic surgery such as a hysterectomy, retraction or inadvertent trauma can injure the femoral nerve as it travels near the pelvic brim. Nerve injury may be due to stretch, compression, or ischemia. Current literature supports that iatrogenic nerve injuries remain a rare but recognized complication of pelvic procedures. Patients with femoral nerve injury present with decreased strength in hip flexion and knee extension, and may also exhibit sensory deficits over the anterior thigh and medial leg. The clinical exam in this case (weak hip flexion and knee extension) suggests an isolated femoral nerve injury. Differential diagnoses include an obturator nerve injury (which would predominantly affect thigh adduction) or lumbar radiculopathy. Electromyography (EMG) and nerve conduction studies are the gold standards to localize the lesion, while imaging (e.g., MRI) can be useful in excluding compressive lesions or hematomas. Initial management involves conservative measures including physical therapy, pain management, and potentially neuromuscular re\u2010education. In severe cases, nerve conduction studies guide further interventions. For patients who are pregnant or lactating, non\u2010pharmacological approaches and physical therapy are preferred, as many medications may be contraindicated or require caution. Option A (Femoral) is correct since the combination of hip flexion and knee extension weakness aligns with femoral nerve involvement. Option B (Obturator) would primarily affect thigh adduction. The lack of information for Options C and D further supports Option A. 1. Isolated femoral nerve injuries typically present with both motor deficits (weakness in hip flexion and knee extension) and sensory loss over the anterior thigh. 2. Pelvic surgeries can risk traction or compressive injury to the femoral nerve. Recent studies emphasize the importance of intraoperative nerve monitoring and meticulous surgical technique to minimize iatrogenic nerve injuries. Updated guidelines recommend early EMG evaluation and a multidisciplinary rehabilitative approach for optimal recovery.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient after radiation therapy with shoulder abduction 4/5, impaired sensation in lateral thumb and lateral forearm, improved index and 3rd finger, flexion 2 nerve impaired.",
    "option_a": "Suprascapular/long thoracic",
    "option_b": "Axillary and lateral antebrachial radial",
    "option_c": "Musculocutaneous",
    "option_d": "",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Injury to parts of the brachial plexus, particularly involving the posterior cord, can affect nerves such as the axillary and radial nerves. The axillary nerve primarily supplies the deltoid (for shoulder abduction), while the superficial branch of the radial nerve provides sensory innervation to the lateral aspect of the thumb and portions of the lateral forearm. Radiation therapy can induce brachial plexopathy through mechanisms of fibrosis, demyelination, and microvascular compromise. The posterior cord, which gives rise to both the axillary and radial nerves, may be particularly vulnerable in the setting of radiation\u2010induced injury. The patient\u2019s shoulder abduction weakness (reduced deltoid strength) coupled with impaired sensation over the lateral thumb and forearm strongly suggests involvement of the posterior cord. This pattern aligns with radiation-induced brachial plexopathy affecting its posterior division. Differential diagnoses include isolated nerve injuries such as a pure axillary nerve lesion (which would not account for lateral thumb sensory loss) or a suprascapular nerve injury (which would affect rotator cuff muscles rather than the sensory distribution described). EMG studies, nerve conduction studies, and magnetic resonance imaging (MRI) can help delineate the lesion\u2019s location and extent. Management is largely supportive, including physical therapy aimed at preserving range of motion and strength. Pain control is optimized with medications that are safe in pregnancy and lactation (e.g., acetaminophen, with caution on NSAIDs if contraindicated). In some cases, corticosteroids or immunomodulatory agents may be considered, though their use in radiation-induced nerve injury is controversial. When managing pregnant or lactating patients, non-pharmacologic therapies and close monitoring are recommended. Option A (Suprascapular/long thoracic) is incorrect because these nerves do not account for lateral thumb sensation. Option B (Axillary and lateral antebrachial radial) almost points to branches of the posterior cord but the terminology is unconventional and does not fully capture the constellation of findings. Option C (Musculocutaneous) does not explain the shoulder abduction deficit. Option D, presumed to denote a lesion of the posterior cord of the brachial plexus, best fits the clinical picture and is therefore correct. 1. Radiation-induced brachial plexopathy often has a delayed onset and may selectively involve particular cords. 2. The posterior cord gives rise to both the axillary and radial nerves, explaining the combined motor and sensory deficits in this patient. Recent literature highlights the complexity of radiation-induced brachial plexopathy and supports the use of advanced imaging (such as MRI) alongside electrodiagnostic studies to accurately map the injury. Current guidelines emphasize individualized conservative management with physical therapy and careful adjustment of any pharmacological treatment in pregnancy and lactation.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with hip flexion weakness, thigh adduction and knee extension weakness, after abdominal surgery, she is on warfarin, where is the lesion.",
    "option_a": "Femoral at illicus",
    "option_b": "Femoral at psoas",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "The lumbar plexus lies within the substance of the psoas muscle, giving rise to both the femoral and obturator nerves. The femoral nerve provides innervation for hip flexion (via the iliopsoas) and knee extension (via the quadriceps), while the obturator nerve is primarily responsible for thigh adduction. In patients on anticoagulation, such as warfarin, even minor trauma or surgery can lead to spontaneous hemorrhage. A psoas hematoma can compress the nerves as they course through the muscle, affecting multiple components of the lumbar plexus. This explains the combination of hip flexion weakness, knee extension weakness, and impaired thigh adduction. The patient, having undergone abdominal surgery while on warfarin, is at risk for developing a psoas hematoma. The clinical deficits \u2013 weakness in hip flexion (reflecting iliopsoas involvement), knee extension (femoral nerve involvement), and thigh adduction (suggesting obturator nerve involvement) \u2013 point to a lesion in the psoas region. Differential diagnoses include an isolated femoral nerve injury (which would not typically cause adductor weakness) or lumbar radiculopathy. CT scan or MRI of the abdomen and pelvis are critical for identifying a psoas hematoma. Electrophysiologic studies can help assess nerve involvement and localize the lesion. The first step is correcting the coagulopathy and stabilizing the patient. Imaging is essential to confirm a psoas hematoma. Conservative management with observation and reversal of anticoagulation is often effective; in cases with significant mass effect or neurological compromise, interventional radiology or surgical decompression may be needed. In pregnant or lactating patients, ionizing radiation exposure during imaging should be minimized with appropriate shielding or alternative imaging modalities, and reversal agents should be used judiciously. Option A (Femoral at iliacus) would typically cause isolated deficits in hip flexion and knee extension without affecting thigh adduction. Option B (Femoral at psoas) correctly accounts for the involvement of both the femoral nerve and the nearby obturator fibers (explaining adduction weakness), making it the best answer. 1. A psoas hematoma is a recognized complication in patients on anticoagulation, particularly following surgery. 2. Combined deficits (hip flexion, knee extension, and thigh adduction) should prompt evaluation for a lesion within the psoas muscle. Recent studies underscore the importance of early imaging in anticoagulated patients with unexplained groin or thigh pain and neurological deficits. Guidelines recommend prompt reversal of coagulopathy and cautious use of interventional treatments to prevent permanent nerve damage.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Male came with stiffness with repeat exercise.",
    "option_a": "Myotonia congenita",
    "option_b": "Paramyotonia",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonic disorders are characterized by delayed muscle relaxation after voluntary contraction. In myotonia congenita, the 'warm\u2010up' phenomenon is typical, where repeated muscle use leads to improvement in stiffness. Myotonia congenita is usually caused by mutations in the CLCN1 gene affecting chloride channels in the muscle membrane. This channelopathy leads to an imbalance in membrane excitability, resulting in prolonged muscle contraction. In contrast, paramyotonia congenita (typically due to sodium channel mutations) is characterized by worsening stiffness with repeated activity. The patient\u2019s history of stiffness that improves with repeated exercise aligns with the 'warm\u2010up' phenomenon seen in myotonia congenita. Patients often report difficulty initiating movement that improves as the limb is used. Differentiation is based on clinical history and electrodiagnostic studies. Myotonia congenita may show characteristic myotonic discharges on EMG with improvement on repeated contractions, whereas paramyotonia congenita shows paradoxical worsening. Differential diagnoses include other non-dystrophic myotonias as well as conditions that cause muscle stiffness (e.g., myositis). Management of myotonia congenita is primarily symptomatic. First-line options include lifestyle modifications and avoiding triggers; pharmacologic treatment with mexiletine (a sodium channel blocker) can be considered based on the latest trials. In pregnancy and lactation, caution is advised with mexiletine due to limited safety data, and non-pharmacologic management is preferred. Option A (Myotonia congenita) is correct as it is characterized by stiffness that improves with repeated exercise (the warm-up phenomenon). Option B (Paramyotonia congenita) is incorrect because it typically worsens with exercise. 1. The warm-up phenomenon \u2013 improvement in muscle stiffness with repeated use \u2013 is pathognomonic for myotonia congenita. 2. Genetic testing can help differentiate between the autosomal dominant (Thomsen) and recessive (Becker) forms. Recent randomized trials have supported the use of mexiletine for symptomatic treatment, though its use in specific populations such as pregnant or lactating women requires careful risk\u2013benefit analysis. Advances in genetic analysis continue to refine the diagnosis and understanding of these channelopathies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of Myotonic Dystrophy came with shoulder pain management",
    "option_a": "Melxiten for pain",
    "option_b": "Amantadine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myotonic dystrophy is a multisystem genetic disorder primarily characterized by myotonia\u2014or delayed muscle relaxation\u2014which leads to stiffness and pain. In patients with myotonic dystrophy, muscle pain (such as shoulder pain) can be directly related to myotonic activity. Mexiletine, a sodium channel blocker, is considered a first\u2010line symptomatic treatment to improve myotonia and, as a result, alleviate associated pain. Myotonic dystrophy (notably type 1) results from a CTG trinucleotide repeat expansion in the DMPK gene, causing abnormal RNA splicing and widespread multisystem effects, including muscle membrane hyperexcitability. Mexiletine reduces this hyperexcitability by blocking sodium channels, thereby improving the myotonic phenomenon and reducing muscle stiffness and pain. Patients with myotonic dystrophy often experience complaints of muscle stiffness, pain, and difficulty with relaxation after contraction. Shoulder pain in this context can be due to persistent myotonia rather than a primary joint or rotator cuff pathology, making mexiletine an appropriate choice. When a myotonic dystrophy patient presents with shoulder pain, the differential diagnosis includes: 1) myotonia-induced musculoskeletal pain, 2) structural shoulder pathology (e.g., rotator cuff tendinopathy or tear), and 3) other secondary causes of musculoskeletal pain. A thorough clinical evaluation, possibly supplemented with imaging, helps in discerning the pain origin. However, in the context of established myotonic dystrophy with myotonia, addressing the abnormal muscle excitability is a priority. The mainstay for managing symptomatic myotonia in myotonic dystrophy is the use of sodium channel blockers like mexiletine. Its efficacy in reducing myotonic discharge leads to improved muscle relaxation and pain relief. When treating women who are pregnant or lactating, careful consideration is necessary. While mexiletine has shown benefit, its safety profile during pregnancy/lactation is not well established, and risks must be weighed against benefits. Alternative non-pharmacologic management and a multidisciplinary approach might be appropriate if safety concerns arise. Option A, labeled as 'Melxiten', is interpreted as a reference to mexiletine, which is supported by evidence as a treatment for myotonia-related pain in myotonic dystrophy. Option B, amantadine, is used primarily in Parkinsonism and for other off-label neurological indications but is not indicated for treating myotonia in myotonic dystrophy. Options C and D were not provided, leaving option A as the best-supported choice. Mexiletine is among the few agents that effectively target the underlying mechanism of myotonia by blocking sodium channels. It is important to evaluate cardiac status in patients with myotonic dystrophy before initiating mexiletine, as these patients may have conduction abnormalities. Special caution is warranted regarding its use during pregnancy or lactation, and consultation with relevant specialists is recommended. Recent trials have confirmed mexiletine\u2019s efficacy in reducing myotonic stiffness and pain in patients with myotonic dystrophy. Clinical guidelines continue to recommend its use for symptomatic myotonia, with monitoring for potential cardiac effects. Ongoing research emphasizes the need for caution in special populations, such as pregnant or lactating women, where the risk\u2013benefit profile must be carefully assessed.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Pt with Picture of LGMD, he underwent 3 surgeries under general anesthesia without complication. His brother after a procedure developed malignant hyperthermia. what to tell the patient.",
    "option_a": "He is not at risk at all since he underwent 3 procedures without complication",
    "option_b": "Still he has the risk",
    "option_c": "He is at high risk",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Malignant hyperthermia (MH) is an inherited pharmacogenetic disorder in which exposure to certain anesthetic agents (notably succinylcholine and volatile anesthetics) triggers a hypermetabolic crisis in skeletal muscle. A family history of MH is a crucial risk factor, as the condition is usually inherited in an autosomal dominant fashion. MH is most commonly linked to mutations in the ryanodine receptor (RYR1) gene, leading to an abnormal release of calcium from the sarcoplasmic reticulum within skeletal muscle cells. This results in sustained muscle contraction, hypermetabolism, acidosis, and hyperthermia. Even if a patient has previously tolerated anesthesia without incident, a positive family history indicates that the underlying susceptibility may still be present. In this case, the patient with a presentation consistent with limb girdle muscular dystrophy (LGMD) has a brother who developed malignant hyperthermia. While LGMD itself is primarily a muscle disease, the concern here is not what the patient\u2019s myopathy alone entails but rather the genetic predisposition to MH. It is important to note that an uneventful anesthetic history does not exclude the risk in someone with a positive family history. The diagnosis of MH susceptibility involves a thorough evaluation of personal and family history, and may be confirmed through specialized contracture testing (e.g., the caffeine-halothane contracture test) or genetic testing for mutations in RYR1 and other related genes. Even if past exposures did not result in a crisis, the existence of a familial case warrants caution. For patients with suspected MH susceptibility, the current guidelines recommend avoidance of triggering agents in future anesthetic procedures. Instead, non-triggering agents (such as those used in total intravenous anesthesia) should be employed. In the context of pregnancy and lactation, similar principles apply: anesthesiologists should plan safe protocols to avoid MH triggers while ensuring maternal and fetal/neonatal safety. Emergency management of an MH crisis includes immediate discontinuation of the trigger, aggressive cooling, and administration of intravenous dantrolene. Option A ('He is not at risk at all since he underwent 3 procedures without complication') is incorrect because previous uneventful anesthetic exposures do not negate the genetic risk posed by a positive family history. Option C ('He is at high risk') exaggerates the risk without taking into account that previous tolerances reduce immediate concern, although caution is still warranted. Option B ('Still he has the risk') is correct because it recognizes that despite prior surgeries without complication, the familial predisposition to MH remains a significant concern. \u2022 A negative history of anesthetic complications does not rule out MH susceptibility if there is a significant family history.\n\u2022 MH is an autosomal dominant disorder often related to RYR1 mutations; therefore, family screening and caution with anesthesia are advised.\n\u2022 In obstetric care, safe, non-triggering anesthetic protocols are essential to protect both mother and child. The latest clinical guidelines emphasize that any patient with a family history of MH should be considered at risk, even if prior surgeries were uneventful. Research continues to support the genetic underpinnings of MH, and current anesthetic management protocols\u2014including the use of dantrolene and avoidance of triggering agents\u2014are standard practice. Pregnancy and lactation management also require the adaptation of these protocols to ensure the safety of both the mother and the fetus/neonate.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient elderly known case of DM uncontrolled came with foot drop, thigh pain and loss wight, most important management",
    "option_a": "IVIG",
    "option_b": "Tight glycemic control, and care of foot",
    "option_c": "Extensive physiotherapy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question involves an elderly patient with uncontrolled diabetes mellitus presenting with foot drop, thigh pain, and weight loss. These symptoms are consistent with a form of diabetic neuropathy, such as diabetic amyotrophy (lumbosacral radiculoplexus neuropathy), which often presents with pain, weakness, and systemic features such as weight loss. In diabetic patients, tight glycemic control and proper foot care are critical for slowing the progression of neuropathy and for preventing serious complications like foot ulcers and infections. Chronic hyperglycemia in diabetes leads to metabolic and vascular changes that cause nerve ischemia and damage. In diabetic neuropathy, especially diabetic amyotrophy, there may also be an inflammatory component affecting the lumbosacral plexus resulting in pain, muscle weakness (leading to foot drop), and muscle atrophy. Microvascular compromise further exacerbates nerve damage. Patients with diabetic neuropathy may exhibit both sensory and motor deficits. Foot drop indicates involvement of motor fibers, while thigh pain and weight loss suggest an underlying systemic neuropathy like diabetic amyotrophy. The combination of these signs in an elderly diabetic patient reinforces the need for improved metabolic control as the primary intervention. Diagnosis is primarily clinical. A detailed neurological examination, nerve conduction studies, and electromyography (EMG) can help differentiate between types of diabetic neuropathy and rule out other conditions such as compressive neuropathies or inflammatory demyelinating conditions. Differential diagnoses include chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barr\u00e9 syndrome in acute presentations, and mononeuritis multiplex from other vasculopathies. The cornerstone of managing diabetic neuropathy, including diabetic amyotrophy, is optimal glycemic control, which helps slow nerve damage progression. Proper foot care is essential to prevent secondary complications like ulcerations and infections. Adjunctive treatments include pain management and physiotherapy. In pregnancy and lactation, maintaining tight glycemic control is crucial and is best managed with insulin, as many oral hypoglycemic agents are contraindicated. Foot care remains a priority to prevent complications, and physiotherapy may be continued with modifications as needed. Option A (IVIG) is typically reserved for immune-mediated neuropathies, such as CIDP, and does not apply to diabetic neuropathy. Option B (tight glycemic control, and care of foot) addresses the primary underlying issue in diabetic neuropathy and is the most important management strategy. Option C (extensive physiotherapy) serves as supportive therapy but does not tackle the metabolic cause. Option D is blank and thus is not considered. In diabetic patients, maintaining strict glycemic control is fundamental to managing neuropathic complications. Foot care is a critical preventive measure to avoid further morbidity. While physiotherapy and pain management are valuable, they are supportive, emphasizing the role of metabolic control as the primary therapy. Recent guidelines underscore the importance of tight glycemic control in mitigating the progression of diabetic neuropathy. Evidence supports that optimal blood sugar management reduces the risk of developing further neuropathic complications and helps in the overall management strategy. Foot care protocols are also well-established to prevent secondary complications. Use of IVIG is not supported for diabetic neuropathy in the absence of clear indications for an immune-mediated process.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Male came with peroral fasciculation, areflexia, systemic manifestation.",
    "option_a": "DM",
    "option_b": "HTN",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical picture described \u2013 peroral (tongue) fasciculations combined with areflexia and systemic manifestations \u2013 is most consistent with a disorder involving the lower motor neurons. In neurology, tongue fasciculations are a classic finding in motor neuron diseases (MND), particularly in variants that involve bulbar regions. Although a typical case of ALS (amyotrophic lateral sclerosis) shows a mix of upper and lower motor neuron signs (with hyperreflexia due to UMN involvement), there are recognized variants (such as progressive muscular atrophy or progressive bulbar palsy) that mainly display LMN features like fasciculations and areflexia. Motor neuron disease (MND) involves the progressive degeneration of motor neurons. In variants with predominant lower motor neuron (LMN) loss, denervation leads to spontaneous discharges that manifest as fasciculations. The loss of LMN input also results in diminished or absent deep tendon reflexes (areflexia). The systemic manifestations such as weight loss, fatigue, and generalized muscle wasting occur as the disease advances. Patients with bulbar-onset MND often present with difficulties in speech and swallowing along with tongue fasciculations. The absence of reflexes is a pointer toward LMN dysfunction. The systemic nature of the disease is reflected in muscle weakness and wasting that progressively compromises respiratory and other functions. A careful neurological examination, electromyography (EMG), and nerve conduction studies are key in confirming LMN degeneration. Differentials to consider include myasthenia gravis (which typically shows fatigable weakness without fasciculations and with preserved reflexes), Guillain\u2013Barr\u00e9 syndrome (which has areflexia but often presents acutely with ascending weakness and without tongue fasciculations), and metabolic neuropathies such as diabetic neuropathy (which usually present with a distal pattern and sensory involvement). There is no cure for MND, but management focuses on slowing disease progression and symptomatic support. Riluzole is approved for ALS and can modestly prolong survival, and edaravone is another agent approved by the FDA. Multidisciplinary supportive care (physical therapy, nutritional support, and respiratory assistance) is paramount. For women who are pregnant or lactating, the use of riluzole (categorized as pregnancy Category C) requires a careful risk\u2013benefit discussion and close monitoring, while breastfeeding considerations should involve evaluating the potential for drug transfer to the infant. Option A (DM) and Option B (HTN) are systemic conditions that do not typically cause focal neuromuscular findings such as tongue fasciculations and areflexia. By elimination and based on the clinical cues, Option C, which represents a motor neuron disease (most likely an ALS variant with predominant LMN signs), is the most appropriate answer. Option D is not provided. \u2022 Tongue fasciculations are a red flag for LMN involvement and should prompt evaluation for motor neuron disease.  \u2022 Pure LMN forms of MND (eg, progressive muscular atrophy) may lack the UMN signs, such as hyperreflexia, that are classically associated with ALS.  \u2022 Systemic features like weight loss and muscle wasting further support a diagnosis of a neurodegenerative process. Recent guidelines endorse the use of riluzole (and edaravone in selected patients) for slowing the progression of ALS. Evidence supports a multidisciplinary approach to care which is crucial in optimizing quality of life. Ongoing research is investigating other neuroprotective agents and supportive therapies. Considerations for use during pregnancy and lactation, although not well established, necessitate individualized risk\u2013benefit analysis and are guided by current FDA recommendations.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with neuropathy after mild car accident, with PMP 22 deletion, pathology findings.",
    "option_a": "Onion bulb",
    "option_b": "Sausage shaped",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question addresses a genetic form of peripheral neuropathy associated with a deletion of the PMP22 gene, which is classically seen in Hereditary Neuropathy with Liability to Pressure Palsies (HNPP). The key pathological feature in HNPP is the formation of tomacula, which are sausage\u2010shaped focal thickenings of the myelin. In HNPP, the deletion of PMP22 leads to abnormal myelin formation. This structural defect makes peripheral nerves exceptionally vulnerable to compression or minor trauma, resulting in focal demyelination and subsequent remyelination. The repeated cycles of damage and repair can lead to the distinctive 'sausage shaped' appearance seen on pathology. Patients with HNPP typically present with recurrent episodes of focal neuropathies triggered by minor trauma or compression (for example, after accidents or prolonged pressure on a limb). The clinical manifestation of neuropathic symptoms in such a setting aligns with the underlying genetic predisposition and the associated pathological findings. Diagnostic evaluation involves a careful history emphasizing recurrent, pressure-induced neuropathies, nerve conduction studies (which may reveal conduction block at common entrapment sites), and confirmation via genetic testing for the PMP22 deletion. Differential diagnoses include Charcot-Marie-Tooth disease type 1 (which presents with onion bulb formations due to repeated demyelination and remyelination but is typically due to PMP22 duplication rather than deletion). Management is largely supportive and preventive. The primary strategy is to avoid situations that can compress nerves or lead to injury. Physical therapy and ergonomic modifications may help reduce episodes of neuropathy. Pregnancy and lactation considerations require careful counseling to minimize nerve compression risks; although no specific contraindicated treatments exist, patients should be educated on posture and activity modification during these periods. Option A (Onion bulb) is incorrect because onion bulb formations are most characteristic of conditions like Charcot-Marie-Tooth disease type 1, associated with PMP22 duplication rather than deletion. Option B (Sausage shaped) is the correct choice as it corresponds to the tomacula seen in HNPP. Options C and D are not provided. 1) PMP22 deletion is the hallmark of HNPP. 2) Sausage\u2010shaped (tomacula) nerve changes are pathognomonic for HNPP. 3) Even minor trauma can provoke neuropathic symptoms in affected individuals. Recent studies and genetic screening protocols continue to support the identification of PMP22 deletions in patients with recurring pressure palsies. Current guidelines stress the importance of early genetic diagnosis and patient education on the avoidance of nerve compression to mitigate chronic damage.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Familial hx of ALS, gene mutation",
    "option_a": "sod1",
    "option_b": "c9orf",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question centers on the genetic mutations associated with familial Amyotrophic Lateral Sclerosis (ALS). While several genes are implicated in familial ALS, it is crucial to note that mutations in the C9orf72 gene have emerged as the most common genetic abnormality in these patients. The C9orf72 gene mutation typically involves a pathological hexanucleotide repeat expansion. This abnormal expansion leads to the production of toxic RNA species and dipeptide repeat proteins that disrupt normal cellular functions and ultimately cause motor neuron degeneration. Patients with a C9orf72 mutation present with typical ALS symptoms such as progressive weakness and motor neuron degeneration. Importantly, this mutation is also associated with a spectrum of frontotemporal dementia symptoms, linking it to cognitive and behavioral changes in some cases. In patients with a family history of ALS, genetic testing is indicated. Differential diagnoses include sporadic ALS, other motor neuron diseases, and mimic conditions such as primary lateral sclerosis. A detailed family history and genetic work-up help differentiate between these conditions. Management of ALS remains largely supportive, as no cure exists. Riluzole and edaravone are among the few disease-modifying therapies approved. Genetic counseling is essential for families with identified mutations. During pregnancy and lactation, management focuses on symptom relief and multidisciplinary care, while drugs like riluzole require careful risk\u2013benefit analysis and close monitoring. Option A (sod1) is a well-known mutation associated with familial ALS but is not the most common mutation. Option B (c9orf) is the correct choice given current evidence, as C9orf72 repeat expansions are the most prevalent genetic abnormality in familial ALS. Options C and D are not provided. 1) C9orf72 repeat expansion is the most common genetic defect in familial ALS. 2) This mutation can also predispose individuals to frontotemporal dementia. 3) Genetic counseling plays a vital role in the management of familial ALS. Current research emphasizes the significant prevalence of the C9orf72 mutation in familial ALS cases. Ongoing clinical trials are investigating gene-targeted therapies, and updated guidelines highlight the importance of genetic testing in the work-up of familial ALS.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Pt came with peripheral neuropathy, his symptoms provoked after minor surgery.",
    "option_a": "Vitamin E",
    "option_b": "Cobalamine",
    "option_c": "Thiamine",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This question highlights a scenario where a patient develops peripheral neuropathy following minor surgery. In such settings, it is critical to consider vitamin deficiencies\u2014especially vitamin B12 (cobalamin)\u2014as a potential underlying factor. B12 deficiency is a well-established cause of peripheral neuropathy and neurological dysfunction. Vitamin B12 is essential for myelin formation and neuronal function. Perioperative exposure to nitrous oxide, an anesthetic agent commonly used even in minor surgeries, is known to inactivate cobalamin by oxidizing its cobalt ion. In patients with pre-existing, possibly subclinical, B12 deficiency, this exposure can precipitate acute or subacute neuropathic symptoms. Patients with B12 deficiency typically present with symptoms of peripheral neuropathy, which may include numbness, tingling, and impaired proprioception. The onset of symptoms following exposure to nitrous oxide during a minor procedure is a recognized clinical scenario that reinforces the link between cobalamin deficiency and postoperative neuropathy. The work-up for suspected B12 deficiency-induced neuropathy includes measuring serum vitamin B12 levels, along with assessment of methylmalonic acid and homocysteine levels. Differential diagnoses include thiamine deficiency (common in alcoholic or malnourished patients) and vitamin E deficiency (often seen with malabsorption syndromes), but the temporal association with surgery (particularly if nitrous oxide was used) provides a strong clue toward cobalamin involvement. Treatment involves prompt vitamin B12 replacement, which can be administered either intramuscularly or orally depending on the severity of the deficiency and absorption capability. In pregnant or lactating women, parenteral supplementation is generally preferred due to concerns about absorption and the need for rapid correction, though benefits must be weighed against risks. Additionally, reviewing anesthesia protocols (e.g., considering alternatives to nitrous oxide) is advised in B12-deficient patients. Option A (Vitamin E) is less commonly a precipitant of acute neuropathy in the post-surgical setting and is more typically associated with malabsorption syndromes. Option B (Cobalamin) is correct because vitamin B12 deficiency can be unmasked or exacerbated by nitrous oxide exposure during surgery, leading to neuropathic symptoms. Option C (Thiamine) deficiency can cause neuropathy (as seen in dry beriberi), but it is less frequently associated with nitrous oxide exposure and the clinical context provided here. 1) Nitrous oxide can acutely inactivate vitamin B12, precipitating neuropathic symptoms in vulnerable individuals. 2) Always assess vitamin B12 levels preoperatively in patients at risk (e.g., the elderly or those with gastrointestinal malabsorption). 3) Early recognition and treatment of B12 deficiency can prevent irreversible neurological damage. Recent studies have reinforced the association between nitrous oxide exposure and the exacerbation of vitamin B12 deficiency. Updated guidelines recommend screening for B12 deficiency in at-risk populations undergoing surgery, and they underscore the importance of careful anesthetic selection in these patients.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of DM came with peripheral neuropathy he has impaired sensation for pinprick up to mid-shin, what has level A Evidence in the treatment of peripheral neuropathy. (Both pregapalin and gapapentin came in choices)",
    "option_a": "Pregabaline",
    "option_b": "Gapapentin",
    "option_c": "Amitriptyline",
    "option_d": "ue to its side effect profile, especially in the elderly.",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This question deals with the management of painful diabetic peripheral neuropathy. The focus is on identifying a treatment option that has Level A evidence \u2013 meaning it is supported by robust clinical trials and guideline recommendations. Pregabalin, along with duloxetine, is one of the first-line treatments approved for diabetic neuropathic pain. Diabetic neuropathy arises from chronic hyperglycemia, which leads to microvascular damage, oxidative stress, and subsequent nerve injury. The resultant abnormal nerve excitability is partially mediated by increased calcium influx through voltage-gated calcium channels. Pregabalin binds to the alpha-2-delta subunit of these channels, reducing the release of excitatory neurotransmitters, thereby alleviating neuropathic pain. Patients typically present with a symmetric, distal sensory loss or dysesthesia, as seen in the impairment of pinprick sensation up to the mid-shin described in the question. Effective management of neuropathic pain is essential for improving quality of life in diabetic patients. The diagnosis is based on clinical history, physical examination, and exclusion of other causes of neuropathy such as nutritional deficiencies, other metabolic derangements, or toxic exposures. Differential diagnoses include peripheral arterial disease, vitamin deficiency neuropathies, and other forms of small fiber neuropathies. Current guidelines (such as those from the American Diabetes Association and other neurology societies) endorse pregabalin and duloxetine as first-line agents for diabetic neuropathic pain (Level A evidence). Pregabalin is preferred because of its robust clinical trial data and FDA approval for this indication. Second-line therapies include gabapentin and tricyclic antidepressants like amitriptyline. In pregnant and lactating women, the use of these agents should be carefully considered due to limited safety data; treatment decisions should be individualized after weighing potential risks and benefits. Option A (Pregabalin) is supported by Level A evidence and is approved for the treatment of diabetic neuropathic pain, making it the correct answer. Option B (Gabapentin) is used off-label for diabetic neuropathy but does not have the same level of evidence as pregabalin for this indication. Option C (Amitriptyline) is a tricyclic antidepressant that may be used as a second-line option due to its side effect profile, especially in the elderly. 1) Pregabalin is a first-line treatment for diabetic neuropathy with robust evidence supporting its use. 2) Maintaining optimal glycemic control is essential in the management of diabetic neuropathy. 3) Always consider pregnancy and lactation safety when initiating neuropathic pain medications. Recent meta-analyses and updated clinical guidelines continue to support the use of pregabalin as a first-line agent for managing diabetic neuropathic pain. Large randomized controlled trials have demonstrated its efficacy and safety profile, which underpins its Level A recommendation in current practice.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient know case of DM came with peripheral neuropathy he has impaired sensation for pinprick up to mid-shin, what test would be best for diagnosis.",
    "option_a": "NCS",
    "option_b": "MRI spine",
    "option_c": "Epidermal nerve fiver density",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Diabetic peripheral neuropathy is a common complication of diabetes mellitus and can affect different types of nerve fibers. When patients present with impaired pinprick sensation, it suggests involvement of small nerve fibers (C and A\u03b4 fibers), which mediate pain and temperature sensation. The epidermal nerve fiber density (ENFD) assessment by skin biopsy is the most sensitive test to diagnose small fiber neuropathy. Chronic hyperglycemia leads to metabolic and microvascular changes that result in axonal degeneration. In particular, small fibers may degenerate early due to oxidative stress and microvascular insufficiency. These changes result in impaired pain and temperature sensation, which is characteristic of small fiber neuropathy. Clinically, patients with diabetic neuropathy often exhibit a 'stocking-glove' distribution of sensory loss. In cases where only small fibers are involved, standard nerve conduction studies (NCS) may be normal because NCS primarily assesses large fiber function. Hence, a patient with impaired pinprick sensation is best evaluated with a skin punch biopsy to measure epidermal nerve fiber density. The differential diagnosis of peripheral neuropathy includes large fiber neuropathies (better captured by NCS/EMG), toxic neuropathies, nutritional deficiencies, and other metabolic disorders. In a diabetic patient with isolated loss of pain sensation, the preservation of large fibers makes ENFD measurement the most useful diagnostic test. MRI of the spine is not indicated in the absence of radicular pain or structural spinal pathology. Management focuses on glycemic control and symptomatic relief. For painful neuropathy, first-line options include gabapentinoids (e.g., pregabalin) or serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine). In pregnant or lactating patients, medication choices require caution with some analgesics; non-pharmacologic measures and tight glycemic regulation are emphasized. Diagnostic tests such as ENFD are safe in all populations. Option A (NCS) is typically used for large-fiber neuropathy and may be normal in pure small fiber involvement. Option B (MRI spine) is not indicated in diabetic neuropathy unless there is suspicion of a compressive etiology. Option C (Epidermal nerve fiber density) is the correct answer as it is the most sensitive test for small fiber neuropathy. 1. In diabetic patients with impaired pain sensation, always consider a small fiber neuropathy workup if NCS is non-diagnostic. 2. The 'stocking-glove' distribution is classical in diabetic neuropathy. 3. Skin biopsy for ENFD is considered the gold standard for diagnosing small fiber neuropathy. Recent studies and guidelines support the use of skin punch biopsy for epidermal nerve fiber density measurement in patients with suspected small fiber neuropathy, particularly when clinical signs (e.g., impaired pinprick sensation) are present despite normal nerve conduction studies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Myasthenia graves scenario ask about medication do not give in case of decreased thiopurine S-methyltransferase (TPMT) enzyme.",
    "option_a": "Azathioprine",
    "option_b": "Mycophenolate",
    "option_c": "Cyclophosphamide",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Myasthenia gravis is an autoimmune disorder affecting the neuromuscular junction. Immunosuppressants play a key role in long\u2010term management. Azathioprine, a purine analogue, requires metabolism by the enzyme thiopurine S-methyltransferase (TPMT). Azathioprine is converted into 6-mercaptopurine and further metabolized by TPMT. A deficiency in TPMT results in accumulation of toxic metabolites, leading to severe myelosuppression, which can cause life-threatening complications. In patients with myasthenia gravis, determining TPMT activity is crucial before initiating azathioprine. Low TPMT activity predisposes patients to significant bone marrow suppression and must alter the therapeutic approach. Assessment involves testing TPMT enzyme levels or genotyping prior to starting azathioprine therapy. Differential considerations for immunosuppressants in myasthenia gravis include mycophenolate mofetil and cyclosporine, which do not rely on TPMT for metabolism. The first-line treatment for myasthenia gravis often includes acetylcholinesterase inhibitors and corticosteroids. When steroid-sparing agents are needed, immunosuppressants such as azathioprine or mycophenolate mofetil are considered. In patients with diminished TPMT activity, azathioprine is contraindicated. In pregnant or lactating women, mycophenolate is generally contraindicated due to teratogenicity, and azathioprine is preferred only if TPMT activity is confirmed to be normal with careful monitoring. Thus, tailoring therapy based on TPMT activity is crucial. Option A (Azathioprine) is contraindicated in patients with decreased TPMT due to the risk of severe myelosuppression. Option B (Mycophenolate) is an alternative but isn\u2019t the one in question. Option C (Cyclophosphamide) is another immunosuppressant with a different toxicity profile and is not the drug that requires TPMT screening. 1. Always screen for TPMT activity before starting azathioprine therapy. 2. Low TPMT activity can lead to life-threatening bone marrow suppression when using azathioprine. 3. Alternative immunosuppressants should be considered in TPMT deficient patients. Current guidelines advocate for TPMT testing prior to azathioprine initiation for autoimmune diseases such as myasthenia gravis. Recent literature consistently shows that TPMT-deficient patients are at higher risk for adverse hematologic events, reinforcing the need for alternative agents when TPMT is low.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly areflexia (tendon reflex un-obtained, ophthalmoplegia, finger to nose test impaired, since 2 days next step, no hx about infection or vaccine. What is the treatment.",
    "option_a": "IVIG",
    "option_b": "Methylprednisolone",
    "option_c": "Ach",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain-Barr\u00e9 syndrome (GBS) is an acute, immune-mediated polyneuropathy. One of its variants, Miller Fisher syndrome, is characterized by a triad of ophthalmoplegia, ataxia, and areflexia. Prompt recognition and management are essential to prevent progression. GBS is believed to result from autoimmune mechanisms triggered by preceding infections or immunizations, leading to demyelination and/or axonal injury of peripheral nerves. In Miller Fisher syndrome, antibodies (such as anti-GQ1b) target components of the peripheral nervous system, leading to the characteristic clinical features. The elderly patient with areflexia, ophthalmoplegia, and impaired coordination (finger-to-nose test) is strongly suggestive of the Miller Fisher variant of GBS. Although many cases of Miller Fisher syndrome may follow a viral infection or vaccination, the absence of such history does not exclude the diagnosis. Typically, rapid progression over days calls for prompt intervention. Diagnosis is based on clinical features, supported by nerve conduction studies and cerebrospinal fluid (CSF) analysis demonstrating albuminocytologic dissociation. Differential diagnoses include brainstem stroke, myasthenia gravis (which lacks ataxia and areflexia), and botulism. Neuroimaging can help rule out central lesions. The mainstay of treatment for GBS, including its Miller Fisher variant, is immunotherapy with either intravenous immunoglobulin (IVIG) or plasmapheresis. Steroids (e.g., methylprednisolone) have not shown benefit. For pregnant or lactating patients with GBS, IVIG is generally preferred due to its safety profile in pregnancy and minimal transfer into breast milk relative to other agents. Option A (IVIG) is the correct treatment as it modifies the immune response in GBS and is supported by several guidelines. Option B (Methylprednisolone) has not demonstrated efficacy in GBS. Option C (Ach, or acetylcholine) is not relevant to the treatment of GBS. 1. Miller Fisher syndrome is a variant of GBS that typically presents with ophthalmoplegia, ataxia, and areflexia. 2. IVIG and plasmapheresis are both first-line treatments for GBS; steroids are not effective. 3. Early intervention is critical to prevent respiratory compromise. Recent updates from neurology guidelines confirm that IVIG is as effective as plasmapheresis in treating GBS, with IVIG being easier to administer and safe in special populations such as pregnant and lactating women.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of Duchenne, first symptoms.",
    "option_a": "Walk on toe",
    "option_b": "Loss fine movement",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder characterized by progressive muscle degeneration due to mutations in the gene coding for dystrophin. Early clinical manifestations revolve around motor difficulties. The absence of dystrophin leads to structural instability of muscle fibers. This results in repeated cycles of muscle fiber damage and regeneration, ultimately leading to muscle weakness and pseudohypertrophy, especially in the calves. The earliest signs of DMD typically include delays in motor milestones, a waddling gait, and toe walking (walking on the toes) due to calf pseudohypertrophy and contractures. Toe walking is often one of the initial observable gait abnormalities in young boys with DMD. Diagnosis is based on clinical examination, elevated creatine kinase (CK) levels, genetic testing, and sometimes muscle biopsy. The differential diagnosis includes Becker muscular dystrophy, spinal muscular atrophy, and other congenital myopathies. The pattern of early proximal muscle weakness with calf pseudohypertrophy supports DMD. Management of DMD includes corticosteroids (such as prednisone) to slow disease progression, physical therapy, and supportive measures. Cardiac and respiratory monitoring are crucial as the disease progresses. In pregnancy or lactation, careful use of corticosteroids is recommended with dose adjustments and close monitoring, while novel therapies are generally contraindicated or used under strict protocols. Option A (Walk on toe) is the correct answer as toe walking is a common early manifestation in DMD attributable to calf muscle involvement and contracture formation. Option B (Loss of fine movement) is less typical early on, as fine motor skills are generally preserved until later in the disease course. 1. Duchenne Muscular Dystrophy typically presents in early childhood with proximal muscle weakness and gait abnormalities such as toe walking and a positive Gower\u2019s sign. 2. Calf pseudohypertrophy is a classic finding due to fat and connective tissue replacement. 3. Early diagnosis is key to initiating interventions that may slow disease progression. Recent guidelines emphasize early multidisciplinary intervention in DMD, including corticosteroid therapy and genetic counseling. Advances in molecular therapies, including exon-skipping therapies, are promising but currently reserved for specific mutation subtypes and under clinical trial settings.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "54 YO male came with neck pain, tingling sensation in bilateral hands, He gave history of small joint pain and swelling, MRI of cervical area are shown. (Exactly the same MRI)",
    "option_a": "Disc Compression",
    "option_b": "Rheumatoid Pannus",
    "option_c": "Spondylosis",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient presenting with neck pain and bilateral hand paresthesias in the setting of a history of small joint pain and swelling \u2013 clues that point toward an inflammatory arthritis. In rheumatoid arthritis (RA), the cervical spine (especially the atlantoaxial joint) can be involved due to inflammatory pannus formation. This pannus is an abnormal layer of granulation tissue that can erode bone and destabilize the joint. In RA, chronic synovial inflammation leads to the formation of a pannus. In the cervical spine, inflammatory pannus formation around the dens and lateral masses leads to bony erosions, ligamentous laxity, and potentially atlantoaxial subluxation. This can cause narrowing of the spinal canal or foramina, resulting in compression of neural elements, which clinically explains the bilateral hand symptoms. Patients with RA may present with systemic small joint involvement and later develop cervical spine symptoms such as neck pain, stiffness, and neurological deficits (e.g., tingling or weakness in the upper extremities). MRI findings in these patients typically demonstrate pannus formation, erosion around the odontoid process and possible subluxation at C1-C2. The workup should include a detailed rheumatologic history and laboratory testing (RF, anti-CCP antibodies), in addition to imaging studies. MRI is the preferred imaging modality for evaluating soft tissue pannus and cord or nerve root compression. Differential diagnoses include degenerative disc disease (disc compression) and spondylosis, but the clinical context of inflammatory arthritis is key to distinguishing rheumatoid pannus. Management revolves around controlling the underlying RA with disease\u2010modifying antirheumatic drugs (DMARDs) and possibly biologic therapies. For cervical involvement, conservative management may include immobilization and anti\u2010inflammatory medications. In cases of significant instability or neurological compromise, surgical stabilization (e.g., cervical fusion) may be indicated. In pregnancy and lactation, many DMARDs are contraindicated; however, agents like hydroxychloroquine or low\u2010dose corticosteroids (with obstetrical consultation) can be used safely. Option A (Disc Compression) is more typical of a degenerative disc herniation and does not fit with the history of small joint involvement. Option B (Rheumatoid Pannus) is correct given the history of joint pain and the known cervical involvement in RA. Option C (Spondylosis) relates to age\u2010related degenerative changes rather than an inflammatory process seen in RA. 1. Always consider cervical spine involvement in patients with rheumatoid arthritis, even if they are asymptomatic. 2. Atlantoaxial subluxation is a feared complication in RA and may be evident on lateral cervical spine imaging. 3. MRI is the imaging modality of choice to assess soft tissue changes and neural compromise in RA. Recent guidelines emphasize early aggressive DMARD therapy to control systemic inflammation and prevent cervical spine complications in RA. Surgical intervention is considered when there is evidence of instability or neurological deficit, and preoperative imaging is critical to guide management.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "ALS came with fatigue next step.",
    "option_a": "Pulmonary function test",
    "option_b": "Methylphenadate",
    "option_c": "Refer to assess depression",
    "option_d": "nocturnal oximetry",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient presenting with neck pain and bilateral hand paresthesias in the setting of a history of small joint pain and swelling \u2013 clues that point toward an inflammatory arthritis. In rheumatoid arthritis (RA), the cervical spine (especially the atlantoaxial joint) can be involved due to inflammatory pannus formation. This pannus is an abnormal layer of granulation tissue that can erode bone and destabilize the joint. In RA, chronic synovial inflammation leads to the formation of a pannus. In the cervical spine, inflammatory pannus formation around the dens and lateral masses leads to bony erosions, ligamentous laxity, and potentially atlantoaxial subluxation. This can cause narrowing of the spinal canal or foramina, resulting in compression of neural elements, which clinically explains the bilateral hand symptoms. Patients with RA may present with systemic small joint involvement and later develop cervical spine symptoms such as neck pain, stiffness, and neurological deficits (e.g., tingling or weakness in the upper extremities). MRI findings in these patients typically demonstrate pannus formation, erosion around the odontoid process and possible subluxation at C1-C2. The workup should include a detailed rheumatologic history and laboratory testing (RF, anti-CCP antibodies), in addition to imaging studies. MRI is the preferred imaging modality for evaluating soft tissue pannus and cord or nerve root compression. Differential diagnoses include degenerative disc disease (disc compression) and spondylosis, but the clinical context of inflammatory arthritis is key to distinguishing rheumatoid pannus. Management revolves around controlling the underlying RA with disease\u2010modifying antirheumatic drugs (DMARDs) and possibly biologic therapies. For cervical involvement, conservative management may include immobilization and anti\u2010inflammatory medications. In cases of significant instability or neurological compromise, surgical stabilization (e.g., cervical fusion) may be indicated. In pregnancy and lactation, many DMARDs are contraindicated; however, agents like hydroxychloroquine or low\u2010dose corticosteroids (with obstetrical consultation) can be used safely. Option A (Disc Compression) is more typical of a degenerative disc herniation and does not fit with the history of small joint involvement. Option B (Rheumatoid Pannus) is correct given the history of joint pain and the known cervical involvement in RA. Option C (Spondylosis) relates to age\u2010related degenerative changes rather than an inflammatory process seen in RA. 1. Always consider cervical spine involvement in patients with rheumatoid arthritis, even if they are asymptomatic. 2. Atlantoaxial subluxation is a feared complication in RA and may be evident on lateral cervical spine imaging. 3. MRI is the imaging modality of choice to assess soft tissue changes and neural compromise in RA. Recent guidelines emphasize early aggressive DMARD therapy to control systemic inflammation and prevent cervical spine complications in RA. Surgical intervention is considered when there is evidence of instability or neurological deficit, and preoperative imaging is critical to guide management.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Patient came with hand extension weakness no sensory",
    "option_a": "PIN",
    "option_b": "Radial",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient presenting with neck pain and bilateral hand paresthesias in the setting of a history of small joint pain and swelling \u2013 clues that point toward an inflammatory arthritis. In rheumatoid arthritis (RA), the cervical spine (especially the atlantoaxial joint) can be involved due to inflammatory pannus formation. This pannus is an abnormal layer of granulation tissue that can erode bone and destabilize the joint. In RA, chronic synovial inflammation leads to the formation of a pannus. In the cervical spine, inflammatory pannus formation around the dens and lateral masses leads to bony erosions, ligamentous laxity, and potentially atlantoaxial subluxation. This can cause narrowing of the spinal canal or foramina, resulting in compression of neural elements, which clinically explains the bilateral hand symptoms. Patients with RA may present with systemic small joint involvement and later develop cervical spine symptoms such as neck pain, stiffness, and neurological deficits (e.g., tingling or weakness in the upper extremities). MRI findings in these patients typically demonstrate pannus formation, erosion around the odontoid process and possible subluxation at C1-C2. The workup should include a detailed rheumatologic history and laboratory testing (RF, anti-CCP antibodies), in addition to imaging studies. MRI is the preferred imaging modality for evaluating soft tissue pannus and cord or nerve root compression. Differential diagnoses include degenerative disc disease (disc compression) and spondylosis, but the clinical context of inflammatory arthritis is key to distinguishing rheumatoid pannus. Management revolves around controlling the underlying RA with disease\u2010modifying antirheumatic drugs (DMARDs) and possibly biologic therapies. For cervical involvement, conservative management may include immobilization and anti\u2010inflammatory medications. In cases of significant instability or neurological compromise, surgical stabilization (e.g., cervical fusion) may be indicated. In pregnancy and lactation, many DMARDs are contraindicated; however, agents like hydroxychloroquine or low\u2010dose corticosteroids (with obstetrical consultation) can be used safely. Option A (Disc Compression) is more typical of a degenerative disc herniation and does not fit with the history of small joint involvement. Option B (Rheumatoid Pannus) is correct given the history of joint pain and the known cervical involvement in RA. Option C (Spondylosis) relates to age\u2010related degenerative changes rather than an inflammatory process seen in RA. 1. Always consider cervical spine involvement in patients with rheumatoid arthritis, even if they are asymptomatic. 2. Atlantoaxial subluxation is a feared complication in RA and may be evident on lateral cervical spine imaging. 3. MRI is the imaging modality of choice to assess soft tissue changes and neural compromise in RA. Recent guidelines emphasize early aggressive DMARD therapy to control systemic inflammation and prevent cervical spine complications in RA. Surgical intervention is considered when there is evidence of instability or neurological deficit, and preoperative imaging is critical to guide management.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "lady who has symptoms of peripheral neuropathy (among other symptoms), and electrophoresis showed the presence of IgM antibody, what is the treatment",
    "option_a": "Prednisolone",
    "option_b": "periodic plasma exchange",
    "option_c": "periodic IVIG",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "This question appears to address a paraprotein\u2010associated peripheral neuropathy, most typically seen with an IgM monoclonal gammopathy. In many such patients \u2013 frequently those with anti\u2010myelin\u2010associated glycoprotein (anti\u2010MAG) neuropathy \u2013 the IgM antibody is pathogenic, leading to a slowly progressive demyelinating polyneuropathy. In IgM-associated neuropathies (especially anti-MAG neuropathy), the IgM antibody binds to myelin\u2010associated glycoprotein on Schwann cells. This antibody binding leads to segmental demyelination, predominantly affecting distal sensory nerves and sometimes motor fibers. The immune-mediated damage results in the clinical picture of a slowly progressive, typically sensory-dominant neuropathy. Patients with anti-MAG (IgM) neuropathy usually present with a chronic, predominantly sensory neuropathy that may be accompanied by a postural tremor and ataxia. Although the condition is more common in older individuals and has a slight male predominance, it can occur in females. Differential diagnoses include chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), the latter of which has an IgM anti-GM1 association and is typically treated with IVIG. The workup involves nerve conduction studies (showing a demyelinating pattern) and serum electrophoresis with immunofixation, which demonstrates a monoclonal IgM band. If available, specific anti-MAG antibody testing is confirmatory. Differential diagnosis should rule out other causes of demyelinating neuropathy such as CIDP or other paraproteinemias. The evidence-based management of anti-MAG neuropathy remains challenging. Although rituximab has emerged as a first-line agent in many recent studies, it is not among the provided options. Among the choices given, periodic IVIG is preferred over prednisolone (which is generally ineffective) and plasma exchange (which only transiently lowers the IgM levels without sustaining clinical benefit). When planning therapy in women of childbearing age, IVIG is generally regarded as safe during pregnancy and lactation, whereas chronic steroids have potential risks and plasma exchange is not typically a long-term strategy. Option A (Prednisolone) has been shown to be largely ineffective in IgM-mediated (anti-MAG) neuropathies. Option B (Periodic Plasma Exchange) can lower antibody titers transiently but does not provide durable benefit and is not considered the standard of care. Option C (Periodic IVIG) is the most acceptable among these choices, as IVIG is used in several immune-mediated neuropathies (e.g., CIDP and sometimes MMN) and may offer symptomatic improvement even though its benefits in anti-MAG neuropathy are modest. \u2022 Anti-MAG neuropathy is a subtype of IgM paraproteinemic neuropathy and typically does not respond well to steroids. \n\u2022 Recent evidence supports rituximab as a first-line treatment, but when limited to options like IVIG and plasma exchange, IVIG is preferred. \n\u2022 IVIG is considered safe for use during pregnancy/lactation if treatment is necessary, whereas long-term plasma exchange is not practical as maintenance therapy. Current studies indicate that while neither plasma exchange nor IVIG is curative in anti-MAG neuropathy, IVIG may provide transient symptomatic improvement in a subset of patients. Meta-analyses and treatment guidelines have not supported the use of long-term periodic plasma exchange, and treatment strategies are now increasingly centered on B-cell depleting therapies such as rituximab. In the absence of rituximab as an option, periodic IVIG is the most evidence\u2010aligned choice among those provided.",
    "exam_year": "2020",
    "exam_type": "Part II"
  }
]